罗欣药业(002793) - 2018 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was CNY 198,635,539.30, a 3.30% increase year-on-year[8] - Net profit attributable to shareholders was CNY 30,675,139.43, up 9.49% compared to the same period last year[8] - Basic earnings per share increased by 7.14% to CNY 0.15 for the reporting period[8] - Diluted earnings per share remained unchanged at CNY 0.14 for the reporting period[8] - The weighted average return on equity was 3.73%, a decrease of 0.18% compared to the previous year[8] - Total operating revenue for Q3 2018 was CNY 198,635,539.30, an increase of 3.5% compared to CNY 192,290,503.57 in the same period last year[41] - Net profit for Q3 2018 reached CNY 30,675,139.43, representing a 9.4% increase from CNY 28,016,939.07 in Q3 2017[42] - Basic earnings per share for Q3 2018 were CNY 0.15, compared to CNY 0.14 in the same quarter last year[42] Assets and Liabilities - Total assets increased by 43.66% to CNY 1,291,411,559.44 compared to the end of the previous year[8] - Total liabilities increased to 416,779,986.81 from 144,741,586.45, suggesting higher leverage[35] - The company's total equity reached CNY 873,368,270.93, up from CNY 753,071,565.63 in the same period last year, marking an increase of 15.9%[39] - The company's total liabilities increased significantly, with the issuance of convertible bonds contributing to a rise in payable bonds to ¥222,888,691.50[16] Cash Flow - Net cash flow from operating activities decreased by 81.94% to -CNY 1,887,992.52 for the reporting period[8] - The net cash flow from operating activities for the third quarter was ¥22,404,551.02, a decrease from ¥26,714,459.00 in the previous year, reflecting a decline of approximately 16.5%[55] - Total cash inflow from financing activities was ¥392,661,832.30, significantly higher than ¥91,278,800.00 in the same period last year, indicating a year-over-year increase of over 330%[59] - The cash flow from financing activities netted ¥299,765,736.14, a significant recovery from a negative cash flow of -¥48,801,060.26 in the previous year[56] Investments and Expenses - Research and development expenses increased by 35.44% to ¥8,814,911.20, reflecting higher investment in R&D activities[17] - Sales expenses rose by 93.76% to ¥7,644,889.07, attributed to increased exhibition and promotional costs[17] - Investment income decreased by 49.87% to ¥2,042,031.52, primarily due to reduced gains from copper futures contracts[17] - Research and development expenses for Q3 2018 were CNY 8,814,911.20, an increase from CNY 6,508,489.36 in Q3 2017, reflecting a focus on innovation[41] Shareholder Information - The total number of shareholders at the end of the reporting period was 17,179[12] - The company's equity attributable to shareholders rose to 874,631,572.63 from 754,185,289.51, indicating improved financial health[35] Other Financial Metrics - The company reported non-recurring gains and losses totaling CNY 1,270,189.23 for the year-to-date[9] - The company reported a financial expense of CNY -8,191,112.76, a significant improvement compared to CNY 5,896,466.46 in the previous year[41] - The total profit for the current period was ¥96,448,558.23, down 10.1% from ¥107,662,884.60 in the previous period[48] - The company reported a decrease in asset impairment losses to ¥4,173,524.43 from ¥7,012,728.61, a reduction of 40.5%[48]